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Abstract
Epidemics of influenza A vary greatly in size and age distribution of cases, and this variation
is attributed to varying levels of pre-existing immunity. Recent studies have shown that anti-
body-mediated immune responses are more cross-reactive than previously believed, and
shape patterns of humoral immunity to influenza A viruses over long periods. Here we quan-
tify antibody responses to the hemagglutinin subunit 1 (HA1) across a range of subtypes
using protein microarray analysis of cross-sectional serological surveys carried out in the
Netherlands before and after the A/2009 (H1N1) pandemic. We find significant associations
of responses, both within and between subtypes. Interestingly, substantial overall reactivity
is observed to HA1 of avian H7N7 and H9N2 viruses. Seroprevalence of H7N7 correlates
with antibody titers to A/1968 (H3N2), and is highest in persons born between 1954 and
1969. Seroprevalence of H9N2 is high across all ages, and correlates strongly with A/1957
(H2N2). This correlation is most pronounced in A/2009 (H1N1) infected persons born after
1968 who have never encountered A/1957 (H2N2)-like viruses. We conclude that hetero-
subtypic antibody cross-reactivity, both between human subtypes and between human and
nonhuman subtypes, is common in the human population.
Introduction
Yearly epidemics of influenza A in temperate regions are notoriously variable in duration, size,
and age distribution of cases [1–5]. This appears to be true for influenza pandemics caused by
novel or reappearing subtypes as well [3, 5–10]. For instance, while mortality rates of 0.5%-
1.0% have been reported for the 1918 pandemic, causing 20–100 million deaths worldwide,
the recent 2009 pandemic was relatively mild, with an estimated overall attack rate of 24% and
estimated mortality rate remaining below 0.01% [6, 9]. Varying levels of pre-existing immun-
ity for the strain that is seeding the pandemic or yearly epidemic are driving the observed
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differences [1, 5, 7–9, 11–14]. Protection to influenza A infection and severity is mediated by
cellular and humoral immune responses, with cellular responses being relatively conserved
across viruses and in time, and antibody responses being more specific and variable [15, 16].
Recent studies, however, show that antibody-mediated immune responses, especially those
directed against the stalk of the hemagglutinin protein (HA), are more cross-reactive than pre-
viously believed [17–39].
To assess the extent of cross-reactivity of antibody responses to historic influenza viruses in
the human population we analyze cross-sectional serological survey data from the Netherlands
obtained before and after the A/H1N1 pandemic of 2009 [7]. The samples had been tested by
hemagglutination inhibition (HI) test using pandemic A/2009 (H1N1) virus as antigen, and by
hemagglutinin subunit 1 (HA1) protein microarray. While HI responses are directed mostly
to the major antibody epitopes on the globular head of HA (i.e. the HA1 subunit), responses of
the microarray are also directed to stalk of HA, which is composed of portions of HA1 and all
of HA2. We analyze sera using HA1 antigens from human H1N1, H2N2, and H3N2, and
avian H5N1, H7N7 and H9N2 viruses [40–42]. Earlier analyses focused on A/1918 (H1N1)
and A/2009 (H1N1) HA1 antigens to investigate diagnostic characteristics of the new tests to
distinguish persons infected during the pandemic of 2009 from those with pre-existing immu-
nity [43], and to estimate infection attack rates and population levels of pre-existing immunity
[8]. The previous studies reveal that a strong correlation exists between the hemagglutination
inhibition test and the HA1 microarray when using pandemic A/2009 (H1N1) virus as anti-
gen, especially in samples of persons that were likely infected with the pandemic virus. More-
over, the microarray offers a sensitive and specific test to distinguish recently infected persons
from those with pre-existing immunity. Here we take into account full response to 12 antigens
in 357 persons, including those to HA1 antigens from avian H5N1, H7N7 and H9N2 viruses.
We focus on correlations that must be caused by cross-reactive responses and cannot be
caused by associations in infection histories, e.g., responses to avian influenza viruses, and
responses against HA1 of A/1957 (H2N2) virus in persons born after 1968, i.e. who are too
young to have been infected naturally.
Materials and methods
The sera used in this paper originate from two age stratified serological surveys that were con-
ducted before and after the influenza pandemic of 2009 [7]. The study was approved by the
Medical Ethical Testing Committee of Utrecht University (Utrecht, the Netherlands), accord-
ing to the Declaration of Helsinki (protocol 66-282/E). Written informed consent was given
by participants (or next of kin/caregiver in the case of children) for suitably anonymized clini-
cal records to be used in this study.
We draw an age stratified random subset of these surveys (167 pre-pandemic samples and
190 post-pandemic samples), oversampling sera with high A/2009 (H1N1) HI titers [43]. Per-
sons who had received pandemic vaccinations were not eligible for selection because of the
interference of vaccination with the microarray test results [41]. Full details on the antibody
protein array have been described earlier [41, 42]. Briefly, antibody titers are calculated from
the inflection point of twofold serial dilution series, with lower and upper dilutions of 1/20 and
1/2560, respectively. Throughout, a sample is said to be seropositive if it has a positive response
in the first 1/20 dilution. Samples that are negative in the first 1/20 dilution are said to be sero-
negative. In the figures, these samples are assigned a titer value of 20, and in the statistical anal-
yses these samples are considered to be left-censored.
For each person in the study, information on age, sex, and municipality of residence was
available from the population register. The participants filled in a questionnaire, containing
Cross-reactivity of influenza A antibodies
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questions on demographic characteristics, living conditions, underlying illness, history of influ-
enza-like illness, and seasonal influenza vaccination history in the preceding five years [7].
Samples are analyzed with nine representative antigens from human viruses and three
avian isolates of main subtypes that are considered a risk of forward human transmission
(H5N1, H7N7, H9N2). Specifically, we include five human H1N1 viruses (A/South Carolina/
1/1918, A/WS/1933, A/New Caledonia/20/1999, A/Brisbane/59/2007, and the pandemic A/
California/06/2009), one H2N2 virus (A/Canada/720/2005, a 1957-like virus), and three H3N2
viruses (A/Aichi/2/1968, A/Wyoming/2/2003, A/Brisbane/10/2007). Table 1 gives an overview
of the antigens included.
Estimates of seroprevalence in the population are based on seropositivity of the test at the
1/20 or 1/40 dilution. In order to calculate population prevalence, weights are assigned to the
individual sera to scale the data back to the population census and the population size of the
HI strata. Confidence intervals for interval estimates of seroprevalence are calculated by the
exact Clopper-Pearson binomial method. Smoothed antibody concentrations and smoothed
seroprevalences are estimated with generalized additive models, using the gamlss procedure of
the gamlss package. Pairwise associations of antibody responses are based on Kendall’s tau, a
non-parametric correlation coefficient. For two measurements in two random subjects Ken-
dall tau has a straightforward interpretation as the difference between the probability for the
measurements to be in the same order and the probability of the measurements being in a dif-
ferent order. This implies that, for example, a value of tau = 0.8 translates to a probability of
(1–0.8)/2 = 0.1 that two measurements in two samples are in different order. Finally, linear
regression analyses are performed using the statistical programming language R.
All data are available at the person-level on GitHub (github.com/mvboven/influenza-
microarray-data). For each person we report sex, age in years, pre- versus post-pandemic sam-
ple, history of seasonal vaccination in the preceding five years, A/2009 (H1N1) HI titer, and
microarray measurements for all 12 antigens. Also included are the population weights used to
estimate population prevalence (see above).
Results
Group 1 viruses
Within group 1 influenza A viruses (H1, H2, H5, and H9), seroprevalence for the similar A/
1918 (H1N1) and A/2009 (H1N1) hemagglutinins are high in both the pre- and post-pandemic
Table 1. Antigens included in the microarray.
Strain Subtype
A/South Carolina/1/1918 H1N1
A/WS/1933 H1N1
A/New Caledonia/20/1999 H1N1
A/Brisbane/59/2007 H1N1
A/California/06/2009 H1N1
A/Canada/720/2005 (1957-like) H2N2
A/Aichi/2/1968 H3N2
A/Wyoming/2/2003 H3N2
A/Brisbane/10/2007 H3N2
A/Vietnam/1194/2004 H5N1
A/Chicken/Netherlands/1/2003 H7N7
A/Guinea fowl/Hong Kong/WF10/1999 H9N2
Overview of the origin of the HA1 antigens included in the antibody protein microarray (reproduced from
[43]). Viruses of avian origin are denoted in bold.
https://doi.org/10.1371/journal.pone.0181093.t001
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surveys in persons 20 years and older (Fig 1)[8, 43]. In persons under 20 years, seroprevalence
is also high in the post-pandemic survey but not the pre-pandemic survey, an observation that
has been exploited earlier to estimate infection attack rates [7, 8]. Seroprevalence for A/2007
(H1N1) is also high across all ages, and does not seem to differ between the pre- and post-
Fig 1. Age-specific antibody titers to group 1 influenza A viruses. Pre- and post-pandemic samples are represented by triangles and
circles, respectively. Red dots indicate that H9N2 titer was40. Solid and dotted lines show weighted seroprevalence estimates and
associated 95% confidence ranges, estimated with a logistic generalized additive model (right axis). Seroprevalence estimates are weighted by
their contribution to the population census [8, 43]. For clarity, only pooled pre- and post-pandemic prevalence estimates are presented.
Antigens (HA1) included are from viruses A/South Carolina/1/1918 (H1N1), A/Canada/720/2005 (H2N2) (1957-like H2N2), A/Brisbane/59/2007
(H1N1), A/California/6/2009 (H1N1), A/Guinea fowl/Hong Kong/WF/10/1999 (H9N2).
https://doi.org/10.1371/journal.pone.0181093.g001
Cross-reactivity of influenza A antibodies
PLOS ONE | https://doi.org/10.1371/journal.pone.0181093 July 17, 2017 4 / 13
pandemic surveys. Highest seroprevalence to A/2007 (H1N1) and highest antibody concentra-
tion measurements are observed in children who were 10–20 year old in 2009. These children
likely had their first influenza infection(s) with A/2007 (H1N1)-like viruses. Seroprevalence and
antibody titers to A/1957 (H2N2) virus (the Asian flu), which circulated from 1957-1968, are
low in persons born after 1965 (who are unlikely to have been infected with H2N2), and much
higher in persons born before 1965 [42]. Interestingly, high seropositivity (40%, 95%CI: 35%-
45%) exists in the Dutch population against the avian H9N2 virus. Seropositivity of H9N2 is
substantial across persons older than 10 years, and peaks in persons 40–60 years with estimated
prevalence exceeding 50% when using a microarray titer cutoff of 20. Seropositivity of H9N2 is
lower when using a higher microarray titer cutoff of 40, but remains high, especially in persons
40–60 years (>30%). Antibody responses to H5N1 virus are low overall (5.1%, 95%CI: 3.1%-
7.9%), and are affected by history of seasonal influenza vaccinations (see below).
Fig 2 shows antibody cross-correlations between 2009 pandemic H1N1 virus, the Asian flu
(H2N2), and the avian H9N2 virus in different age groups. Antibody responses against H2N2
and H9N2 viruses are strongly correlated in both surveys, especially in persons under 45 years
(tau = 0.75 for both surveys, p<10−4 for both surveys). As these persons cannot have been
infected naturally, these responses must result from a correlated response after infection with
another virus. It is tempting to speculate that this is the pandemic H1N1 virus, as seropositivity
against H2N2 or H9N2 in all but a handful of sera also implies seropositivity to the H1N1
virus. In young children (5–9 years) these patterns are even more pronounced. In this age
group, all sera are seronegative (i.e. have no measurable antibodies) to the H1N1, H2N2, and
H9N2 viruses in the pre-pandemic survey (n = 15 samples), and 17 of 26 samples (65%) is
seropositive in the post-pandemic survey. Of these, 6 are also positive for the H2N2 and H9N2
viruses. Similar results are observed in older children (10–19 years). In adults over 45 years
who are likely to have experienced a natural H2N2 infection, the correlation between H2N2
and H9N2 is less pronounced, with low correlation coefficients of 0.18 and 0.24. In these per-
sons, the H2 response is usually substantially higher than the H9 response.
Group 2 viruses
For group 2 influenza viruses (H3, H7), seroprevalence against H3N2 viruses is high across all
age groups, reaching 100% in many age strata (Fig 3). Seronegative persons are only found in
children (<20 years) with regard to their A/1968 (H3N2) response, and in adults over 40 years
with regard to young H3N2 (2003, 2007) viruses. Antibody titers against A/1968 (H3N2) peak
in persons born between 1954 and 1969. As children in the Netherlands contract their first
influenza infection between 1 and 7 years [44], it is likely that a large fraction of persons born
between 1954 and 1969 (and especially those born between 1961 and 1967) had their first
influenza A infection(s) with 1968 H3N2-like viruses. The same holds for H3N2 (2003) virus,
for which antibody titers are highest in persons born between 1989 and 1999. These persons
likely had their first influenza infection with 2003 H3N2-like virus. Remarkably, seropreva-
lence against the avian H7N7 virus, albeit lower than against H9N2 virus, is substantial overall
(population estimate: 10%, 95CI: 7.2%-14%%), and peaks in persons born between 1954 and
1969 (20%, 95%CI: 13%-28%). The peak coincides with the peak in A/1968 (H3N2) antibody
titers.
Correlations between avian viruses
Fig 4 shows correlations of antibody responses to avian viruses (H5N1, H7N7, H9N2). Inter-
estingly, there is a strong correlation between the H9N2 and H7N7 responses, especially in
older persons, even though these viruses belong to different influenza A subtype groups
Cross-reactivity of influenza A antibodies
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(group 1 versus group 2). Seropositivity to H5N1 is low overall, as only a handful of samples
(n = 21) have measurable antibody titers to this virus. There is no noticeable correlation
between H5N1 and H9N2, or between H5N1 and H9N2. Analysis of the data by vaccination
status in the preceding five years shows that seasonal influenza vaccination has an impact on
H5N1 antibody titers. In fact, a linear regression model explaining H5N1 antibody titers by age
Fig 2. Correlations of antibody responses to group 1 influenza viruses. Results are given for age groups 5-44 years (above the
diagonal) and 45+ years (below the diagonal). Black dots: pre-pandemic survey; red dots: post-pandemic survey. In each panel, Kendall’s tau
is given for the pre- and post-pandemics surveys (black and red). Notice the strong positive correlation between H2N2 and H9N2 antibody
titers in persons up to 45 years, i.e. persons who are unlikely to have experienced a natural H2N2 infection. Positive antibody titers to H2N2
and H9N2 are found almost exclusively in persons with positive A/2009 (H1N1) response, suggesting that A/2009 (H1N1) infection yields a
response that is cross-reactive with both H2N2 and H9N2.
https://doi.org/10.1371/journal.pone.0181093.g002
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and number of seasonal vaccinations received in the preceding five years shows that vaccinated
persons have significantly higher H5N1 antibody titer than unvaccinated persons (p<0.001).
No such dependencies on vaccination history are found for the avian H7N7 (p = 0.29) and
H9N2 (p = 0.45) strains.
Fig 3. Age-specific antibody titers to group 2 influenza A viruses. Red dots indicate an H7N7 titer40. Seroprevalence to H3N2 viruses
reaches 100% in most age strata. Solid and dotted lines show the mean weighted antibody concentrations and associated 95% confidence
ranges, estimated with a generalized additive model. For H7N7, solid and dotted lines show interval population-weighted seroprevalence
estimates and associated 95% confidence bounds (right axis). Antigens (HA1) included are from viruses A/Aichi/2/1968 (H3N2), A/Wyoming/
2003 (H3N2), A/Brisbane/10/2007 (H3N2), and A/Ck/Netherlands/2003 (H7N7).
https://doi.org/10.1371/journal.pone.0181093.g003
Cross-reactivity of influenza A antibodies
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Discussion
Correlations in the antibody responses to different influenza viruses may arise by cross-reac-
tivity of responses after infection by one virus, or by associations in infection histories (e.g., it
is more likely that you are infected with virus Y if you have been infected with virus X). In gen-
eral, it is difficult to distinguish between the two explanations. In some cases, however, anti-
body response associations can only be the result of cross-reactivity, either because the virus of
Fig 4. Correlations of antibody responses to avian influenza A viruses. Results are given for age groups 5-44 years (above the
diagonal) and 45+ years (below the diagonal). Black dots: pre-pandemic survey; red dots: post-pandemic survey. In each panel, Kendall’s tau
is given for the pre- and post-pandemics surveys (black and red). Notice that all persons with positive H7N7 response also have a positive
H9N2 response. Antigens included are from viruses A/Vietnam/1194/2004 (H5N1), A/Chicken/Netherlands/1/2003 (H7N7), and A/Guinea
fowl/Hong Kong/WF10/1999 (H9N2).
https://doi.org/10.1371/journal.pone.0181093.g004
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interest has not circulated in the human population, or because the virus has not been in circu-
lation in certain age strata (H2N2 in persons born after 1968, A/2009 (H1N1) in the pre-pan-
demic serological survey). Here we have exploited these observations to explore cross-reactivity
of antibody responses to influenza A viruses in a (structured) random sample from the Dutch
population.
Our analyses have uncovered 1) that HA1 antibodies that react to avian H7N7 and H9N2
viruses are present in a significant part of the Dutch population, 2) that infection with 2009
pandemic H1N1 virus often induces measurable antibodies to HA1 of H2 and H9 viruses, and
3) that seroprevalence to H7 virus is high in persons born between 1954 and 1969. Our results
are in line with earlier finding of ‘original antigenic sin’ and ‘antigenic seniority’, i.e. antibody
responses are generally strongest to those viruses encountered early in life, and with the related
recent concept of ‘antigenic landscapes’, i.e. antibody responses after primary infection extend-
ing beyond the extent of intrinsic cross-reactivity [1, 11–13, 30, 38, 39, 45].
All results reported here are based on a protein microarray test based on the HA1 subunit
of the hemagglutinin. As with the hemagglutination inhibition assay, measurements based on
this test are not necessarily protective. It is known, however, that responses in the microarray
correlate well with corresponding HI titers [41–43]. In our data, we found a strong correlation
between microarray titers and (standardized) HI titers when using A/2009 (H1N1) antigen,
with a (standardized) HI titer of 40 translating roughly to a microarray titer of 80 [43]. It is
also known that there is a positive relation between HI titers and protective immunity, and it
is sometimes stated that a HI titer of 40 would translate to a 50% probability of protective
immunity [46]. If the above reasoning would prove true, one could argue that A/2009 (H1N1)
microarray titer of 80 or more is expected to be protective in 50% of persons. Supporting this
line of reasoning is provided by the observation that the HA1 subunit includes the immunodo-
minant globular head of the hemagglutinin, which contains the four (or five) main antibody
epitopes that are traditionally believed to provide sterilizing immunity.
We included three avian influenza viruses in this study that belong to nonhuman subtypes
(H5N1, H7N7, H9N2). These viruses have caused numerous human infections, and might
develop into fully human transmissible viruses. It may seem plausible that there will be little
antibody-mediated pre-existing immunity in the population to these viruses (but see e.g., [33,
47]). If one would extend the above lines of reasoning for A/2009 (H1N1) to other antigens,
one could argue that there would indeed be limited immunity to H7 viruses in the Dutch pop-
ulation, as only a handful of participants have a microarray titer80, mainly in the persons
born between 1954 and 1969 (Fig 3). For H9, on the other hand, a substantial fraction (30/
3578.4%) of the population has high microarray titers of80, which could translate into pro-
tective immunity. For H5, seroprevalence is very low (5.1% at a microarray titer threshold of
20), and modulated by seasonal vaccination. Interestingly, however, the correlation of H5N1
in older persons (over 44 years) is strongest with the A/1918 (H1N1) and the A/1933 (H1N1)
antigens, with Kendall correlations of tau = 0.33 and tau = 0.46, respectively. Together, these
finding support the recent observation that the incidence of severe H5N1 and H7N9 infections
is lower than expected in age groups that had their first infections with viruses from the same
antigenic family (i.e. H1/H2 in case of H5N1 and H3 in case of H7N9) [48].
Finally, our results shed some light on recent studies on broadly reactive and broadly neu-
tralizing antibodies on the hemagglutinin protein, in particular on HA2 but to a lesser extent
also on HA1 [17–32, 34]. These studies have mostly used animal models and laboratory experi-
ments to study heterosubtypic antibody responses. Here we have added that these findings are
not only found in animals in the laboratory and selected populations (e.g., [34, 47]), but that
cross-reactivity can be estimated quantitatively in the human population. Our data thus lend
additional evidence to the hypothesis that as humans age and accumulate infections, antibody
Cross-reactivity of influenza A antibodies
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responses become increasingly directed to more conserved parts of the hemagglutinin, and
thereby more cross-reactive [11, 12, 18, 30]. This may or may not translate to reduction in
infection attack rates in elderly, but does not generally translates to decreasing rates of disease
probably because of declining overall health in the elderly.
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